Retatrutide
Also known as: LY3437943
Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptor) showing exceptional weight loss results in clinical trials. It represents the next generation beyond tirzepatide.
Research Status
Phase 3 clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Most common during dose escalation, typically resolves within 1-2 weeks as the body adapts. Occurs in 40-50% of users. Manage by eating smaller, frequent meals; avoiding fatty or greasy foods; and staying hydrated. Take anti-nausea medication (e.g., ginger, vitamin B6) if needed. Usually improves significantly by week 3-4 of each dose level.
Occurs in approximately 5-15% of users, usually during the first 2-4 weeks of treatment or after dose increases. If vomiting persists beyond 48 hours or is severe, contact a healthcare provider. Ensure adequate hydration to prevent dehydration. May indicate need to slow titration schedule.
Reported in 20-30% of users, typically mild and self-limiting. Related to slowed gastric emptying and increased GLP-1 signaling. Manage with increased fiber intake, hydration, and over-the-counter antidiarrheal agents if needed. Usually resolves within 1-2 weeks.
Can occur in 10-15% of users, particularly during dose escalation. Manage with increased water intake (aim for 2-3 liters daily), dietary fiber, and light physical activity. Over-the-counter stool softeners or osmotic laxatives (e.g., polyethylene glycol) are safe options. Contact healthcare provider if constipation persists beyond 1 week.
This is an intended pharmacological effect and the primary mechanism for weight loss. Appetite suppression is dose-dependent and typically increases with each titration step. Ensure adequate protein and micronutrient intake despite reduced appetite to prevent malnutrition.
Occurs in 5-10% of users. Minimize by rotating injection sites systematically, using proper injection technique, and allowing the solution to reach room temperature before injection. Most reactions resolve within 24-48 hours. Apply ice if swelling occurs. Avoid injecting into the same site repeatedly.
Reported in approximately 5-10% of users, often during the first 1-2 weeks of treatment. Usually self-resolving. Ensure adequate hydration and sleep. Over-the-counter analgesics (acetaminophen or ibuprofen) are safe if needed.
Occurs in 5-8% of users, particularly during rapid weight loss or if caloric intake is too restricted. Ensure adequate protein intake (minimum 1.2g per kg body weight), sufficient sleep, and gradual caloric deficit rather than extreme restriction. Usually improves with time and proper nutrition.
May occur due to rapid weight loss, dehydration, or electrolyte imbalance. Ensure adequate fluid and electrolyte intake. Rise slowly from sitting or lying positions. If dizziness persists or worsens, contact a healthcare provider to rule out orthostatic hypotension.
Rare but serious adverse event reported in GLP-1 and glucagon agonists. Symptoms include severe upper abdominal pain, back pain, nausea, and vomiting. Seek immediate medical attention if these symptoms occur. Risk may be higher in individuals with personal or family history of pancreatitis. Discontinue immediately if pancreatitis is suspected.
Rapid weight loss increases gallstone formation risk. Symptoms include right upper quadrant pain, nausea, and vomiting. Maintain gradual weight loss (1-2 lbs per week) rather than rapid loss. Ensure adequate fat intake (20-30% of calories) to promote gallbladder emptying. Seek medical evaluation if abdominal pain occurs.
Uncommon in non-diabetic individuals due to glucose-dependent insulin secretion. Risk increases significantly if combined with insulin or sulfonylureas. Diabetic users may require dose adjustment of concurrent medications. Symptoms include shakiness, sweating, rapid heartbeat, and confusion. Always carry fast-acting carbohydrates (glucose tablets, juice) if at risk.
Glucagon signaling can increase heart rate. Reported in 5-10% of users. Usually mild and transient. Monitor heart rate regularly. Contact healthcare provider if heart rate remains elevated (>100 bpm at rest) or if accompanied by chest pain or shortness of breath.
Can result from nausea, vomiting, or diarrhea. Symptoms include dry mouth, dark urine, dizziness, and fatigue. Maintain consistent fluid intake of at least 2-3 liters of water daily. Electrolyte-containing beverages (e.g., coconut water, sports drinks) may help. Seek medical attention if dehydration symptoms persist.
Occasionally reported with GLP-1 agonists. Usually self-resolving within 1-2 weeks. Maintain good oral hygiene and stay hydrated. Contact healthcare provider if taste changes persist beyond 2 weeks.
Can occur with rapid weight loss due to nutritional stress. Ensure adequate protein (1.2-1.6g per kg), iron, zinc, and B vitamins. Hair loss typically reverses 3-6 months after stabilizing weight. Consider biotin or multivitamin supplementation. Contact healthcare provider if hair loss is severe or persistent.
Rapid weight loss without adequate protein intake can result in lean muscle loss. Minimize by consuming 1.2-1.6g protein per kg body weight daily and engaging in resistance training 2-3 times per week. Prioritize protein at each meal.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 0.5-12 mg |
| Frequency | Once weekly |
| Timing | Any time, with or without food |
| Route | Subcutaneous |
Progressive titration: start 0.5mg, increase every 4 weeks. Max dose 12mg in trials.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Half-life | 5-6 days (approximate, based on Phase 2 data) |
Retatrutide is a triple receptor agonist that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple activation enhances insulin secretion in response to glucose, slows gastric emptying to increase satiety, and increases energy expenditure through glucagon signaling. The combined effect produces superior weight loss and metabolic improvements compared to dual GLP-1/GIP agonists like tirzepatide.
GIP Receptor Agonism
Activates GIP receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, improving glycemic control without hypoglycemia risk when glucose is normal. Also acts on adipose tissue to promote energy expenditure.
GLP-1 Receptor Agonism
Slows gastric emptying to increase satiety and reduce appetite, decreases hepatic glucose production, and enhances insulin secretion. This is the primary mechanism driving weight loss in GLP-1 agonists.
Glucagon Receptor Agonism
Increases energy expenditure and fat oxidation, particularly in brown adipose tissue. Glucagon signaling promotes lipolysis and thermogenesis, contributing to the superior weight loss profile of retatrutide versus dual agonists.
- Retatrutide is a novel triple agonist; it activates three distinct metabolic pathways simultaneously, unlike tirzepatide (GIP/GLP-1 dual agonist)
- Phase 2 clinical trials showed mean weight loss of 17-22% at the 12mg dose over 48 weeks, compared to 20-22% for tirzepatide at 15mg
- The glucagon component increases energy expenditure and may reduce compensatory metabolic adaptation seen with GLP-1 monotherapy
- Retatrutide maintains glucose-dependent insulin secretion, minimizing hypoglycemia risk in non-diabetic individuals
- Weekly subcutaneous dosing allows for convenient self-administration and consistent pharmacokinetics
Track your Retatrutide research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Retatrutide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.